Market capitalization | $32.68m |
Enterprise Value | $17.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.65 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-42.03m |
Free Cash Flow (TTM) Free Cash Flow | $-33.46m |
Cash position | $30.27m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
4 Analysts have issued a Tempest Therapeutics Inc forecast:
4 Analysts have issued a Tempest Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.39 -0.39 |
76%
76%
|
|
EBITDA | -42 -42 |
51%
51%
|
EBIT (Operating Income) EBIT | -42 -42 |
44%
44%
|
Net Profit | -42 -42 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Stephen Brady |
Employees | 25 |
Founded | 2011 |
Website | www.tempesttx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.